IO Biotech Reports Five-Year Survival Data for IO102-IO103 Vaccine in Metastatic Melanoma Trial
I'm PortAI, I can summarize articles.
IO Biotech Inc. announced five-year clinical outcomes from the Phase 1/2 MM1636 trial in Nature Communications. The study evaluated the IO102-IO103 vaccine in combination with PD-1 blockade for metastatic melanoma. Results showed a median progression-free survival of 25.5 months, a median duration of response over 53 months, and a median overall survival of 60 months. These findings supported the FDA Breakthrough Therapy Designation for IO102-IO103 with pembrolizumab and the ongoing Phase 3 IOB-013/KN-D18 trial.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments